HealthEquity, Inc. (NASDAQ:HQY – Get a rating) – Barrington Research analysts cut their first-quarter 2023 EPS estimates for HealthEquity shares in a research note released to investors on Thursday, April 21. Barrington Research analyst A. Paris. Jr now expects the company to earn $0.03 per share for the quarter, down from its previous forecast of $0.07. Barrington Research also released HealthEquity earnings estimates for Q3 2023 at $0.19 EPS and Q4 2023 earnings at $0.17 EPS.
EquityHealth (NASDAQ:HQY – Get a rating) last released its quarterly earnings data on Tuesday, March 22. The company reported EPS of $0.09 for the quarter, meeting analysts’ consensus estimate of $0.09. The company posted revenue of $203.30 million for the quarter, compared to $199.27 million expected by analysts. HealthEquity posted a positive return on equity of 3.49% and a negative net margin of 5.85%. In the same period a year earlier, the company posted earnings per share of $0.30.
Other analysts have also published research reports on the company. Deutsche Bank Aktiengesellschaft raised its price target on HealthEquity from $62.00 to $66.00 and gave the company a “buy” rating in a Thursday, March 24 research report. Zacks Investment Research upgraded HealthEquity from a “strong sell” rating to a “buy” rating and set a price target of $58.00 on the stock in a Tuesday, February 8 research report. BTIG Research upgraded HealthEquity from a “neutral” rating to a “buy” rating and set a price target of $85.00 on the stock in a Wednesday, March 30 research report. Guggenheim began covering HealthEquity in a research report on Wednesday, April 6. They have set a “buy” rating and a price target of $89.00 on the stock. Finally, Jefferies Financial Group raised its price target on HealthEquity from $62.00 to $80.00 and gave the stock a “buy” rating in a Monday, March 28 research report. One equity research analyst rated the stock with a sell rating, another issued a hold rating and thirteen gave the company a buy rating. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $77.33.
Shares of NASDAQ HQY opened at $66.73 on Monday. The company has a market capitalization of $5.59 billion, a price/earnings ratio of -125.91, a PEG ratio of 5.97 and a beta of 1.09. The company has a quick ratio of 2.29, a current ratio of 2.29 and a leverage ratio of 0.50. HealthEquity has a 52-week low of $36.81 and a 52-week high of $84.78. The company’s 50-day moving average is $60.24 and its two-hundred-day moving average is $57.15.
A number of large investors have recently bought and sold shares of HQY. Carroll Investors Inc acquired a new position in HealthEquity in the fourth quarter worth $25,000. IndexIQ Advisors LLC acquired a new position in HealthEquity in the fourth quarter worth $27,000. Pinebridge Investments LP acquired a new position in HealthEquity in the fourth quarter worth $31,000. Exchange Traded Concepts LLC increased its stake in HealthEquity by 50.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 990 shares of the company valued at $44,000 after acquiring 330 additional shares in the last quarter. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main acquired a new position in HealthEquity in the fourth quarter worth $68,000. 96.68% of the shares are currently held by hedge funds and other institutional investors.
About HealthEquity (Get a rating)
HealthEquity, Inc provides technology service platforms to consumers and employers in the United States. The Company offers cloud-based platforms for individuals to make healthcare savings and spending decisions, pay healthcare bills, compare treatment options and prices, receive benefits personalized and clinical information, earn wellness incentives, increase savings, and make investment choices; and health savings accounts.
Get news and reviews for HealthEquity Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for HealthEquity and related companies with MarketBeat.com’s FREE daily email newsletter.